Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

BACKGROUND: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m(2) in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and pacl...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, S M, Wortman, B G, Bosse, T, Powell, M E, Singh, N, Hollema, H, Wilson, G, Chowdhury, M N, Mileshkin, L, Pyman, J, Katsaros, D, Carinelli, S, Fyles, A, McLachlin, C M, Haie-Meder, C, Duvillard, P, Nout, R A, Verhoeven-Adema, K W, Putter, H, Creutzberg, C L, Smit, V T H B M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834053/
https://www.ncbi.nlm.nih.gov/pubmed/29190319
http://dx.doi.org/10.1093/annonc/mdx753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834053/
https://www.ncbi.nlm.nih.gov/pubmed/29190319
http://dx.doi.org/10.1093/annonc/mdx753

Ejemplares similares